Literature DB >> 3092906

Haem arginate in the treatment of acute hepatic porphyrias.

P Mustajoki, R Tenhunen, O Tokola, G Gothoni.   

Abstract

Entities:  

Mesh：

Year:  1986        PMID： 3092906      PMCID： PMC1341312          DOI： 10.1136/bmj.293.6546.538-a

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN： 0267-0623


× No keyword cloud information.
  3 in total

Review 1.  Use of hematin in the acute attack of the "inducible" hepatic prophyrias.

Authors:  C J Watson; C A Pierach; I Bossenmaier; R Cardinal
Journal:  Adv Intern Med       Date:  1978

2.  Treatment with haematin in acute hepatic porphyria.

Authors:  K E McColl; M R Moore; G G Thompson; A Goldberg
Journal:  Q J Med       Date:  1981

3.  Hereditary hepatic porphyrias in Finland.

Authors:  P Mustajoki; P Koskelo
Journal:  Acta Med Scand       Date:  1976
  3 in total
  13 in total

1.  Pro-oxidant and antioxidant factors in acute intermittent porphyria: family studies.

Authors:  E Rocchi; P Ventura; A Ronzoni; M C Rosa; C Gozzi; L Marri; G Casalgrandi; M D Cappellini
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

Review 2.  Guide to drug porphyrogenicity prediction and drug prescription in the acute porphyrias.

Authors:  Stig Thunell; Erik Pomp; Atle Brun
Journal:  Br J Clin Pharmacol       Date:  2007-06-19       Impact factor: 4.335

3.  Effect of heme arginate administration on blood pressure in spontaneously hypertensive rats.

Authors:  R D Levere; P Martasek; B Escalante; M L Schwartzman; N G Abraham
Journal:  J Clin Invest       Date:  1990-07       Impact factor: 14.808

4.  Differential effects of metalloporphyrins on messenger RNA levels of delta-aminolevulinate synthase and heme oxygenase. Studies in cultured chick embryo liver cells.

Authors:  E E Cable; J A Pepe; N C Karamitsios; R W Lambrecht; H L Bonkovsky
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808

5.  Audit of the Use of Regular Haem Arginate Infusions in Patients with Acute Porphyria to Prevent Recurrent Symptoms.

Authors:  Joanne T Marsden; Simon Guppy; Penelope Stein; Timothy M Cox; Michael Badminton; Tricia Gardiner; Julian H Barth; M Felicity Stewart; David C Rees
Journal:  JIMD Rep       Date:  2015-03-12

6.  Haem arginate improves hepatic oxidative metabolism in variegate porphyria.

Authors:  O Tokola; P Mustajoki; J J Himberg
Journal:  Br J Clin Pharmacol       Date:  1988-12       Impact factor: 4.335

7.  Acute intermittent porphyria in two patients on anticonvulsant therapy and with normal erythrocyte porphobilinogen deaminase activity.

Authors:  A L Herrick; K E McColl; M R Moore; M J Brodie; A R Adamson; A Goldberg
Journal:  Br J Clin Pharmacol       Date:  1989-04       Impact factor: 4.335

8.  RNAi-mediated silencing of hepatic Alas1 effectively prevents and treats the induced acute attacks in acute intermittent porphyria mice.

Authors:  Makiko Yasuda; Lin Gan; Brenden Chen; Senkottuvelan Kadirvel; Chunli Yu; John D Phillips; Maria I New; Abigail Liebow; Kevin Fitzgerald; William Querbes; Robert J Desnick
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-12       Impact factor: 11.205

Review 9.  Acute Hepatic Porphyria.

Authors:  D Montgomery Bissell; Bruce Wang
Journal:  J Clin Transl Hepatol       Date:  2015-03-15

10.  Preclinical Development of a Subcutaneous ALAS1 RNAi Therapeutic for Treatment of Hepatic Porphyrias Using Circulating RNA Quantification.

Authors:  Amy Chan; Abigail Liebow; Makiko Yasuda; Lin Gan; Tim Racie; Martin Maier; Satya Kuchimanchi; Don Foster; Stuart Milstein; Klaus Charisse; Alfica Sehgal; Muthiah Manoharan; Rachel Meyers; Kevin Fitzgerald; Amy Simon; Robert J Desnick; William Querbes
Journal:  Mol Ther Nucleic Acids       Date:  2015-11-03       Impact factor: 10.183
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.